Cognivue® to Partner on Another Major Clinical Study with the Global Alzheimer’s Platform Foundation
Cognivue Clarity®, a non-invasive and repeatable digital cognitive assessment tool that can assess cognitive functioning and amyloid presence, will be evaluated in the Bio-Hermes-002 study.
October 30, 2024
Cognivue, Inc. announces strategic partnership with the Global Alzheimer’s Platform (GAP) as we participate in the Bio-Hermes-002 clinical trial study. As a GAP study partner, Cognivue will join Biogen and other participating…